問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chung Shan Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 402Taichung CityTaichung South

Recruiting Trial

175Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

500Cases

2023-08-01 - 2027-04-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-09-15 - 2026-10-01

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-12-01 - 2025-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2024-09-01 - 2029-02-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting3Sites

2022-02-28 - 2026-12-10

Phase I/II

Active
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

  • Condition/Disease

    Advanced Non-small Cell Lung Cancer、EGFR Mutation、HER2 Mutation

  • Test Drug

    BAY 2927088

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated3Sites

2023-01-16 - 2025-08-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting13Sites

Terminated5Sites

2026-04-01 - 2030-01-15

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2024-01-15 - 2029-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

1 24 25 26 27 28 50
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB